These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38405106)

  • 1. Interleukin-8 Promoter Polymorphism -251 A/T and Treatment Response in Neovascular Age-related Macular Degeneration.
    Thomsen AK; Krogh Nielsen M; Liisborg C; Sørensen TL
    Clin Ophthalmol; 2024; 18():537-543. PubMed ID: 38405106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
    Wang VM; Rosen RB; Meyerle CB; Kurup SK; Ardeljan D; Agron E; Tai K; Pomykala M; Chew EY; Chan CC; Tuo J
    Mol Vis; 2012; 18():2578-85. PubMed ID: 23112570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline characteristics and progression of neovascular age-related macular degeneration in patients receiving over 60 intravitreal injections of anti-vascular endothelial growth factor.
    Prahs P; Brandl C; Helbig H; Volz C
    Rom J Ophthalmol; 2023; 67(3):260-266. PubMed ID: 37876508
    [No Abstract]   [Full Text] [Related]  

  • 4. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
    Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
    Front Immunol; 2021; 12():738521. PubMed ID: 34721402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-VEGF therapy for age-related macular degeneration].
    Fursova AZ; Chubar NV; Tarasov MS; Vasilyeva MA; Gusarevich OG
    Vestn Oftalmol; 2018; 134(6):59-67. PubMed ID: 30721202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
    Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
    Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA; Ramachandran V; Ismail P; Mohd Isa H; Chan YM; Ngah NF; Md Bakri N; Ching SM; Hoo FK; Wan Sulaiman WA; Inche Mat LN; Hazmi Mohamed M
    Bosn J Basic Med Sci; 2018 Aug; 18(3):260-267. PubMed ID: 29579408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of inflammatory cytokines in the aqueous humour for management of macular diseases.
    Yi QY; Wang YY; Chen LS; Li WD; Shen Y; Jin Y; Yang J; Wang Y; Yuan J; Cheng L
    Acta Ophthalmol; 2020 May; 98(3):e309-e315. PubMed ID: 31531945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.
    Lotery AJ; Gibson J; Cree AJ; Downes SM; Harding SP; Rogers CA; Reeves BC; Ennis S; Chakravarthy U;
    Ophthalmology; 2013 Dec; 120(12):2637-2643. PubMed ID: 24070809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between inflammatory cytokines in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Mao J; Chen N; Zhang S; Fang Y; Zheng Z; Wu S; Ye X; Chen Y; Chen Y; Shen L
    Front Med (Lausanne); 2022; 9():973025. PubMed ID: 36213652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina.
    Demir N; Sevincli S; Kayhan B; Sonmez M
    Cutan Ocul Toxicol; 2021 Jun; 40(2):135-139. PubMed ID: 33944638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cataract surgery in neovascular AMD: impact on visual acuity and disease activity.
    Tang HY; Rosén M; Granstam E
    BMC Ophthalmol; 2023 Jun; 23(1):276. PubMed ID: 37328798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal metabolic and structural alterations in response to aflibercept treatment in neovascular age-related macular degeneration.
    Jakobsen DB; Torp TL; Stefansson E; Peto T; Grauslund J
    Acta Ophthalmol; 2019 Aug; 97(5):525-531. PubMed ID: 30549221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
    Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
    BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining response to anti-VEGF therapies in neovascular AMD.
    Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
    Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective analysis of OCT parameters after intravitreal anti-VEGF inhibitors in neovascular AMD patients in a real-world setting.
    Lüke JN; Alquoqa H; Alsamman A; Aljabary B; Schaub F; Heindl LM
    Int Ophthalmol; 2023 Jan; 43(1):13-25. PubMed ID: 35781595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.